It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. Timeline of Otsuka's History 2014~Present

About OtsukaTimeline of Otsuka's History

  • CorpCorporate
  • PhPharmaceutical business
  • NCNutraceutical business



BeanStalk Kids Center OSAKA opened

Opened as Otsuka Pharmaceutical's first in-house child care center in Tokushima


Samsca introduced in Japan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Vasopressin V2-receptor antagonist

Strategic alliance with IBM in the Central Nervous System (CNS) field

DELTYBA launched in Europe and Japan

Treatment for multidrug-resistant tuberculosis (MDR-TB)

NUEDEXTA launched in U.S.

Pseudobulbar affect (PBA)


Milical launched in Japan

Milical sold in Japan is imported from France-based Nutrition et Santé

Brazil-based Jasmine joined group

EQUELLE launched

Calorie Mate recognized with Good Design Long Life Design Award 2014



Tatsuo Higuchi appointed president and representative director of Otsuka Pharmaceutical Co. Ltd. in addition to existing role as president, representative director and CEO of Otsuka Holdings


U.S.-based Avanir Pharmaceuticals, Inc. joined group

Abilify Maintena launched

Antipsychotic drug

Otsuka Australia Pharmaceutical Pty Ltd Opens in Australia

Otsuka Pharmaceutical opens its first office in Australia, furthering the company's aim of bringing innovative new treatments to patients in Oceania.

REXULTI launched in the U.S.

Adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia.


U.S.-based FoodState joined group

ORONAMIN C DRINK began production and sales in South Korea

ORONAMIN C DRINK marks its 50th Anniversary in Japan

ORONAMIN C DRINK began sales in Hong Kong

Otsuka Pharmaceutical subsidiary Nutrition & Santé (N&S) acquired BIOCENTURY, a leading Spanish health and functional foods company



Donated funds for a Rural Health Center in Myanmar

The facility aims to provide stable maternal and child health services including promotion of midwife-assisted childbirth and health education for local residents.

Otsuka Joins UN Global Compact (UNGC)*

Otsuka Holdings Co., Ltd. became a signatory to the United Nations Global Compact (UNGC) in order to express its commitment to corporate social responsibility (CSR) and sustainability.

  • The Global Compact is an encouragement for companies to pursue sustainable growth and be a good member of society.


Otsuka's U.S. subsidiary Astex Pharmaceuticals, Inc., enters into a clinical collaboration with Genentech.

Clinical trial collaboration in the treatment of acute myeloid leukemia.

Oraltag launched in the U.S.

Oral contrast agent for abdominal CT scans

RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launched in Kobe, Japan.

ICLUSIG® Tablets 15 mg launched in Japan

Drug for chronic myeloidlLeukemia and Philadelphia postive acute lymphoblastic leukemia

Otsuka signed Japan-exclusive license agreement with Takara Bio

License agreement for the investigational cancer treatment HF10, an Oncolytic Virus

Otsuka Pharmaceutical and Akebia Therapeutics, Inc. entered into a collaboration to develop and commercialize Vadadustat in the U.S.

License agreement for vadadustat, an oral hypoxia-inducible factor (HIF) stabilizer, treatment of anemia associated with chronic kidney disease (CKD).


Otsuka Pharmaceutical forms joint venture company for functional food and beverages in the Philippines

SOYJOY Crispy launched in Japan

Soy bar with the pleasant crunchy texture of puffed soy

POCARI SWEAT and ORONAMIN C DRINK recognized with Good Design Long Life Design Award 2016



Otsuka certified as Excellent Health and Productivity Management Enterprise

The Excellent Health and Productivity Management Enterprise Program was jointly instituted by the Ministry of Economy, Trade and Industry (METI) and Nippon Kenko Kaigi. The program certifies legal entities such as companies that implement quality management practices for ensuring a healthy workforce.


Mikeluna® combination ophthalmic solution launched in Japan

Drug for glaucoma and ocular hypertension

Health Canada Approves Otsuka and Lundbeck's REXULTI®

(brexpiprazole) as a treatment for schizophrenia in adults Antipsychotic drug

Otsuka Pharmaceutical acquired Neurovance, Inc., a U.S. privately held, venture-funded, clinical stage pharmaceutical company.

Aiming to widen Otsuka's presence in mental health


Introduced BODYMAINTÉ Brand with the conditioning food BODYMAINTÉ Jelly

BODYMAINTÉ Jelly, a conditioning food to support athletic performance